ClinicalTrials.gg
CompletedNCT07784062Updated Aug 31, 2026

The Effect of Lactase-Treated Feeds on Feeding Intolerance in Preterm Infants

An interventional study of Lactase enzyme and Distilled water in Feeding Intolerance in Preterm Infants, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
0 Days to 28 Days
Sex
All
01

Study summary

The purpose of this study is to evaluate whether adding lactase enzyme to milk feeds can improve feeding tolerance in preterm neonates. Preterm infants may have immature gastrointestinal function and reduced intestinal lactase activity, which may contribute to difficulty digesting lactose and symptoms of feeding intolerance. In this study, eligible preterm neonates will be randomly assigned to receive either lactase-treated milk feeds or placebo-treated milk feeds. Feeding tolerance will be assessed using clinical and nutritional parameters during the study period. The study will compare the two groups to determine whether lactase supplementation improves feeding tolerance and supports better progression of enteral feeding in preterm neonates. The hypothesis is that lactase-treated feeds will reduce feeding intolerance and facilitate achievement of adequate enteral feeding compared with placebo.

Read the detailed description

This is a randomized, controlled, parallel-group interventional study designed to evaluate the effect of lactase-treated feeds on feeding intolerance in preterm neonates.

Preterm neonates are at increased risk of feeding intolerance because of gastrointestinal immaturity, delayed gastric emptying, immature intestinal motility, and incomplete development of digestive enzyme activity. Lactase activity may be relatively low in preterm infants, potentially resulting in incomplete lactose digestion and contributing to gastrointestinal symptoms associated with feeding intolerance.

Eligible preterm neonates will be enrolled according to predefined inclusion and exclusion criteria. Participants will be randomly allocated into two groups. The intervention group will receive milk feeds treated with lactase enzyme, while the control group will receive milk feeds treated with placebo. The placebo will consist of distilled water administered in an equivalent manner to the lactase preparation.

The study will evaluate feeding tolerance throughout the study period. Clinical parameters related to feeding tolerance will be recorded, including the occurrence and severity of feeding intolerance manifestations and the progression of enteral feeding. Nutritional and growth-related parameters will also be assessed according to the study protocol.

The primary objective is to determine whether lactase-treated feeds improve feeding tolerance in preterm neonates compared with placebo-treated feeds. Secondary objectives include evaluating the effect of lactase supplementation on the progression of enteral feeding and selected nutritional and growth outcomes.

The study is expected to provide evidence regarding whether exogenous lactase supplementation may be beneficial in preterm neonates experiencing feeding intolerance

02

Conditions studied

  • Feeding Intolerance in Preterm Infants

Keywords

  • Feeding intolerance Preterm infants
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age \<34 weeks.
  • ≥2 symptoms suggestive of lactose intolerance: abdominal distension, abdominal pain, diarrhea, or diaper/nappy dermatitis.
  • Feeding intolerance defined by GRV >3 mL/kg or the specified vomiting/stool/abdominal-distension.

Exclusion criteria

Exclusion Criteria:

  • Severe congenital malformations, including GI or cardiac defects.
  • NEC according to Bell's staging criteria.
  • Congenital diarrhea.
  • Hemodynamic instability requiring inotropes.
  • Amino-acid-based or lactose-free formula.
  • Guardian declines consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Lacrase treated feeds

    Preterm neonates randomly assigned to this group will receive enteral feeds treated with lactase enzyme

    Drug: Lactase enzyme

  • Placebo comparator
    Placebo

    Preterm neonates randomly assigned to the control group will receive enteral feeds treated with an equivalent volume of sterile distilled water as placebo.

    Other: Distilled water

Interventions

  • Lactase enzyme treated feeds

  • OtherDistilled water

    Distilled water administered as placebo to the control group during enteral feeding.

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in gastric residual volume

    Gastric residual volume measured in milliliters before feeding and serially during the intervention period. The outcome will be assessed by comparing the change in gastric residual volume from baseline between the lactase-treated feed group and the placebo group.

    Time frame: From start of intervention till 2 weeks

  2. Number of participants with abdominal distension

    Abdominal distension assessed clinically by serial abdominal examination and abdominal circumference measurement during the intervention period. Participants with clinically evident abdominal distension will be recorded.

    Time frame: From initiation of intervention to 2weeks

  3. Number of participants with vomiting

    Vomiting episodes will be assessed by clinical observation during the intervention period and recorded for each participant.

    Time frame: From initiation of intervention to 2 weeks

  4. Number of participants with diarrhea

    Diarrhea will be assessed clinically according to stool frequency and consistency during the intervention period and recorded for each participant.

    Time frame: From initiation of intervention to 2 weeks

Secondary outcomes

  1. Mean change from baseline in body length

    Body length measured in centimeters using a standardized infant length board. Length will be assessed at baseline and at the end of the intervention period.

    Time frame: From initiation of the study intervention till 2 weeks

  2. Mean change from baseline in body weight

    Body weight measured in grams using a calibrated neonatal weighing scale. Weight will be measured serially during the study period and the change from baseline will be compared between the lactase-treated feed group and the placebo group.

    Time frame: From initiation of intervention to 2 weeks

  3. Mean change from baseline in head circumference

    Head circumference measured in centimeters using a non-stretchable measuring tape placed around the largest occipital-frontal circumference. Measurements will be obtained at baseline and at the end of the intervention period.

    Time frame: From initiation of intervention to 2 weeks

  4. Mean change from baseline in mid-upper arm circumference

    Mid-upper arm circumference measured in centimeters using a non-stretchable measuring tape at the midpoint of the upper arm. Measurements will be obtained at baseline and at the end of the intervention period.

    Time frame: From initiation of intervention to 2 weeks

07

Study locations

1 site
  • NICU of Ain shams university hospitals
    Cairo, Cairo Governorate 02, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Nov 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2026
First posted
Aug 25, 2026
StartActual
Nov 20, 2025
Primary completionActual
Nov 30, 2025
CompletionActual
Jun 10, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07784062
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Nov 20, 2025
Primary completion
Nov 30, 2025
Completion
Jun 10, 2026
Last update
Aug 31, 2026

Study contacts

Ola Galal
study director · NICU of Ain shams university hospitals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lactase

Start the discussion